{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:35:48Z","timestamp":1792802148440,"version":"4.5.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Interferon type I (IFN-I) signaling system hyperactivation plays an important role in the pathogenesis of juvenile dermatomyositis (JDM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim of the study<\/jats:title><jats:p>To analyze IFN-I score with disease activity in patients with JDM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Clinical manifestations laboratory data, and treatment options were analyzed in 15 children with JDM. Disease activity was assessed by CMAS (childhood myositis assessment tool) and CAT (cutaneous assessment tool) scores. IFN I-score was assessed by RT-PCR quantitation of 5 IFN I-regulated transcripts (IFI44L, IFI44, IFIT3, LY6E, MXA1).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All patients had skin and muscle involvement, some had a fever (<jats:italic>n<\/jats:italic> = 8), swallowing disorders (<jats:italic>n<\/jats:italic> = 4), arthritis (<jats:italic>n<\/jats:italic> = 5), calcinosis (<jats:italic>n<\/jats:italic> = 3), lipodystrophy (<jats:italic>n<\/jats:italic> = 2), and interstitial lung disease (<jats:italic>n<\/jats:italic> = 5). Twelve patients had elevated IFN I-score and it was correlated with skin disease activity. Ten patients had clinically active disease and the level of IFN I-score and its components were higher than in patients with inactive disease (8.8 vs. 4.2, <jats:italic>p<\/jats:italic> = 0.011). IFN I-score was evaluated in nine patients during follow-up. The simultaneous reduction of IFN I-score and its components, CMAS and CAT scores was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Skin involvement in refractory JDM is a challenging problem requiring the use of additional medications. Serum IFN I-score might be suggested as the promising biomarker of skin disease activity in JDM patients. Further investigations on patients with JDM and recurrent disease activity are needed, especially concerning biomarkers that determine the response to JAK inhibitors and treatment options for patients who don\u2019t respond to them.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1214920","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T04:15:44Z","timestamp":1707884144000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Interferon type I signature associated with skin disease in juvenile dermatomyositis"],"prefix":"10.3389","volume":"11","author":[{"given":"Rinat","family":"Raupov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Suspitsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Preobrazhenskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Kostik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"B1","first-page":"351","author":"Petty","year":"2016","journal-title":"Textbook of pediatric rheumatology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","article-title":"Incidence and prevalence of inflammatory myopathies: a systematic review.","volume":"54","author":"Meyer","year":"2015","journal-title":"Rheumatology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/MD.0b013e31827f264d","article-title":"The clinical phenotypes of the juvenile idiopathic inflammatory myopathies.","volume":"92","author":"Shah","year":"2013","journal-title":"Medicine."},{"key":"B4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort.","volume":"84","author":"Tansley","year":"2017","journal-title":"J Autoimmun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/BOR.0000000000000540","article-title":"Dermatomyositis etiopathogenesis: a rebel soldier in the muscle.","volume":"30","author":"Pinal-Fernandez","year":"2018","journal-title":"Curr Opin Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts).","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med."},{"key":"B7","first-page":"668","article-title":"Classification criteria for polymyositis and dermatomyositis.","volume":"22","author":"Tanimoto","year":"1995","journal-title":"J Rheumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"International myositis classification criteria project consortium, the Euromyositis register and the juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland). 2017 European league against rheumatism\/american college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10067-016-3530-4","article-title":"Juvenile dermatomyositis: a tertiary center experience.","volume":"36","author":"Barut","year":"2017","journal-title":"Clin Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20035","article-title":"Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies.","volume":"62","author":"Rider","year":"2010","journal-title":"Arthritis Care Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/art.20397","article-title":"Juvenile dermatomyositis disease activity collaborative study group. Normal scores for nine maneuvers of the childhood myositis assessment scale.","volume":"51","author":"Rennebohm","year":"2004","journal-title":"Arthritis Rheum."},{"key":"B12","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/art.23340","article-title":"Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis.","volume":"59","author":"Huber","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/jid.2011.440","article-title":"Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM.","volume":"132","author":"Goreshi","year":"2012","journal-title":"J Invest Dermatol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12010008","article-title":"Clues to disease activity in juvenile dermatomyositis: neopterin and other biomarkers.","volume":"12","author":"Khojah","year":"2021","journal-title":"Diagnostics."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.1969","article-title":"Updated role of high-frequency ultrasound in assessing dermatological manifestations in autoimmune skin diseases.","volume":"102","author":"Chai","year":"2022","journal-title":"Acta Derm Venereol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00296-019-04315-7","article-title":"Correlation between circulating fibrocytes and dermal thickness in limited cutaneous systemic sclerosis patients: a pilot study.","volume":"39","author":"Ruaro","year":"2019","journal-title":"Rheumatol Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/art.42050","article-title":"Identification of similarities between skin lesions in patients with antisynthetase syndrome and skin lesions in patients with dermatomyositis by highly multiplexed imaging mass Cytometry.","volume":"74","author":"Patel","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000811","article-title":"Distinct interferon signatures stratify inflammatory and dysimmune myopathies.","volume":"5","author":"Rigolet","year":"2019","journal-title":"RMD Open."},{"key":"B19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4274\/balkanmedj.galenos.2023.2023-4-78","article-title":"Type I interferonopathies in childhood.","volume":"40","author":"Ha\u015flak","year":"2023","journal-title":"Balkan Med J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/annrheumdis-2020-218582","article-title":"Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis.","volume":"80","author":"Ding","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1093\/rheumatology\/keab116","article-title":"JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.","volume":"60","author":"Le Voyer","year":"2021","journal-title":"Rheumatology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","article-title":"A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-\u03b1 monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients.","volume":"73","author":"Higgs","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity.","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1093\/rheumatology\/keab601","article-title":"Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response.","volume":"61","author":"Lerkvaleekul","year":"2022","journal-title":"Rheumatology."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/ar3531","article-title":"Type I interferon pathway in adult and juvenile dermatomyositis.","volume":"13","author":"Baechler","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis.","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/acr2.1011","article-title":"Interferon chemokine score and other cytokine measures track with changes in disease activity in patients with juvenile and adult Dermatomyositis.","volume":"1","author":"Crowson","year":"2019","journal-title":"ACR Open Rheumatol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02160-9","article-title":"Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies.","volume":"22","author":"Kim","year":"2020","journal-title":"Arthritis Res Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis.","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1093\/rheumatology\/keaa657","article-title":"Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis?","volume":"60","author":"Heinen","year":"2021","journal-title":"Rheumatology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients.","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.820586","article-title":"The safety and efficacy of tofacitinib in 24 cases of pediatric rheumatic diseases: single centre experience.","volume":"10","author":"Kostik","year":"2022","journal-title":"Front Pediatr."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1214920\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T04:15:47Z","timestamp":1707884147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1214920\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":32,"alternative-id":["10.3389\/fmed.2024.1214920"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1214920","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]},"article-number":"1214920"}}